Cynata Therapeutics see their organ rejection study published
04 Sep 2019 - Clinical-stage biotechnology company Cynata Therapeutics (ASX:CYP) is excited to have a scientific paper published on the efficacy of Cymerus MSCs in a preclinical model of organ transplant rejection.